Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Flagship U.S. facility will include biologic manufacturing and late stage research and clinical development of innovative cancer medicines
The move strengthens GBL’s clinical-stage presence in the United States
While Merck can appeal, Halozyme said it expects the order to hold
The Cranbury facility represents a strategic advancement of the company's operations in the Unted States
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
Subscribe To Our Newsletter & Stay Updated